Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Baudax Bio (Nasdaq: BXRX) announced that Gerri Henwood, its President and CEO, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 9:20 a.m. ET. A live webcast can be accessed via the investors section on the Baudax Bio website, with a replay available for 30 days post-event.

Baudax Bio, focusing on therapeutics for acute care, launched its first product, ANJESO, in June 2020. The company has a robust pipeline including two novel neuromuscular blocking agents and an intranasal dexmedetomidine.

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will participate in a fireside chat at the virtual Oppenheimer 31^st Annual Healthcare Conference on Thursday, March 18, 2021 at 9:20 a.m. ET.

A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be made available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO^® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

 

FAQ

What is the date and time of the Baudax Bio fireside chat at the Oppenheimer Conference?

The Baudax Bio fireside chat is scheduled for March 18, 2021, at 9:20 a.m. ET.

Where can I watch the Baudax Bio fireside chat?

The fireside chat can be viewed live on the 'Presentations' page in the investors section of the Baudax Bio website.

What is ANJESO, and when was it launched by Baudax Bio?

ANJESO is a once-daily IV NSAID that was launched in June 2020 after receiving FDA approval in February 2020.

What does Baudax Bio focus on in terms of pharmaceutical development?

Baudax Bio focuses on therapeutics for acute care settings, including pain management and neuromuscular blocking agents.

How long will the replay of the Baudax Bio fireside chat be available?

The replay will be available for 30 days following the event.